drugset / Trial / NCT06825312
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
Phase 4
Active not recruiting
600 enrolled
Liaoning Chengda Biotechnology CO., LTD
Zhejiang Provincial Center for Disease Control and Prevention · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules. Furthermore, the study will assess the immunogenicity and antibody persistence of primary immunization across different Japanese encephalitis vaccination schedules, as well as the immunogenicity following booster immunizations within these schedules. The safety of each vaccine dose will also be evaluated.
Timeline
- Start
- 2023-11-11
- Primary completion
- 2030-12-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC51 | Vaccine | 0.5 ml | Subcutaneous |
| Subject | Japanese Encephalitis Vaccine (Vero Cell), Inactivated | Vaccine | 0.5 ml | Intramuscular |